Latest Biotech News

Two major year‑end licensing deals reshaped late‑2025 headlines: Sanofi paid $80 million upfront and up to $1.04 billion in biobucks to license ADEL’s tau‑targeting antibody ADEL‑Y01 for...

Immunome reported decisive Phase III results showing its oral gamma‑secretase inhibitor reduced the risk of disease progression or death by 84% in patients with progressing desmoid tumors. The...

Sanofi moved to license ADEL Inc.’s tau‑targeting antibody ADEL‑Y01, paying $80 million up front with the deal carrying potential total payments up to $1.04 billion. ADEL‑Y01 is a humanized...

Genentech struck a multi‑year collaboration with Caris Life Sciences to accelerate discovery of drug targets and biomarkers across solid tumors, a deal valued at up to $1.1 billion including...

XOMA Royalty announced an agreement to acquire Generation Bio in a cash tender offer around $4.29 per share and to provide contingent value rights that capture potential upside from Generation...

Kyverna reported a registrational trial readout showing its personalized CD19 CAR‑T improved mobility and reduced stiffness in stiff person syndrome (SPS), a rare autoimmune disorder. The Phase...

Sanofi disclosed that its BTK inhibitor tolebrutinib failed a Phase III Perseus study in primary progressive multiple sclerosis (PPMS) and warned that the U.S. regulatory review in non‑relapsing...

AI drug discovery startup Chai Discovery closed a $130 million Series B led by Oak HC/FT and General Catalyst at a $1.3 billion valuation to expand its computational design platform. The company...

DBV Technologies announced Phase III success for its epicutaneous peanut allergy patch in a trial enrolling more than 650 children, a milestone that sets the company up for another FDA submission...

Nektar reported that rezpegaldesleukin narrowly missed statistical significance in its Phase 2b Rezolve‑AA trial for severe alopecia areata but said post‑hoc analyses excluding four ineligible...

Adaptive Biotechnologies signed two multi‑year agreements with Pfizer to license its T‑cell receptor (TCR) discovery platform and TCR‑antigen mapping data. Under the first agreement, Pfizer will...

The FDA granted a label expansion for Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan), clearing the antibody-drug conjugate for use in combination with pertuzumab as a first-line...

Roche subsidiary Genentech struck a multi‑year discovery collaboration with Caris Life Sciences to identify drug targets in solid tumors. The pact includes upfront and near‑term payments to Caris...

XOMA Royalty announced a planned acquisition of Generation Bio, offering roughly $4.29 per share and contingent value rights tied to cash and milestone streams from Generation Bio’s...

Kyverna Therapeutics reported positive registrational‑scale results for its autologous CD19 CAR‑T in stiff person syndrome (SPS), an autoimmune neurological disorder with no approved therapies....

Immunome announced top‑line Phase III results showing its oral gamma‑secretase inhibitor produced an 84% reduction in the risk of disease progression or death versus placebo in progressing desmoid...

Swedish drugmaker Sobi agreed to acquire Arthrosi Therapeutics for $950 million upfront, with up to $550 million in additional milestones tied to pozdeutinurad’s Phase III progress and commercial...

AI drug design firm Chai Discovery closed a $130 million Series B at a $1.3 billion valuation to scale its computational platform, including the recently released Chai 2 model for antibody design....

Pfizer disclosed plans to launch 15 new studies in obesity next year, including multiple Phase III programs, as it seeks to shore up revenue facing a looming patent cliff. The initiative signals...

Two preclinical advances highlight growing sophistication in mRNA therapeutics. A team reported a tumor‑selective modified RNA translation system (SMRTS) that programs mRNA to activate therapeutic...